Helus Pharma Inc. (HELP)

Helus Pharma Announces Completion of Legal Name Change

Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depression

Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member Board

Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change

Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member Board

Helus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit

Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026

Cybin Eyes Q4 Phase III Depression Readout as Psychedelic Pipeline Advances

Cybin Eyes Q4 Phase 3 Data for Depression Drug HLP003

Cybin Eyes Q4 Phase III Depression Readout as Psychedelic Pipeline Advances

Insider Buying: Cybin (NASDAQ:HELP) Insider Purchases $1,239,000.00 in Stock

Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New York

Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York

Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York

Helus Pharma: An Undervalued Psychedelic Platform Approaching A Major Catalyst

Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board

Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights

Helus Pharma Appoints Michael Halstead as Chief Executive Officer

Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule

Helus Pharma: APPROACHing Inflection: Pivotal Readout Sets Up Asymmetric Upside